Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

CRISPR01:59

CRISPR

53.0K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
53.0K
CRISPR/Cas9 Genome Editing01:28

CRISPR/Cas9 Genome Editing

375
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
375
Homologous Recombination02:31

Homologous Recombination

52.7K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
52.7K
CRISPR and crRNAs02:53

CRISPR and crRNAs

17.5K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
17.5K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Survival Following Neoplastic Disease in Individuals With Neurofibromatosis 1-A National Danish Population-Based Cohort Study.

International journal of cancer·2026
Same author

Muscle fitness and physical function in children and adolescents with newly diagnosed cancer.

Frontiers in pediatrics·2026
Same author

EHA Recommendations for preconceptual and antenatal screening and prenatal diagnosis for hemoglobinopathies.

HemaSphere·2026
Same author

Clinical Heterogeneity and Outcome of acquired PRCA: a Multicenter European Study.

Blood advances·2026
Same author

No overall increased risk of death in individuals with sickle cell trait: a study of 467 779 general population adults.

Blood·2026
Same author

Deep Sequencing of FLT3-ITD Enables Response Evaluation and Post-Treatment Monitoring in Childhood AML: An Exploratory Study.

Pediatric blood & cancer·2026

相关实验视频

Updated: Sep 18, 2025

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

3.7K

[CRISPR作为治疗血红蛋白病的功能疗法]

Andreas Glenthøj1,2, Sarah Birgitte Ingemod Sand Carlsen1, Marianne Hoffmann3

  • 1Dansk Center for Røde Blodceller, Afdeling for Blodsygdomme, Københavns Universitetshospital - Rigshospitalet.

Ugeskrift for laeger
|June 20, 2025
PubMed
概括
此摘要是机器生成的。

克里斯普尔基因编辑为状细胞疾病和β-血症提供了潜在的治疗方法. 目前的ex vivo疗法受限于可访问性,但未来的in vivo方法可能会在全球范围内提供可扩展,可负担的解决方案.

更多相关视频

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.4K
Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
08:27

Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9

Published on: April 10, 2018

13.6K

相关实验视频

Last Updated: Sep 18, 2025

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
08:32

CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications

Published on: August 9, 2022

3.7K
Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models
08:14

Lentiviral CRISPR/Cas9-Mediated Genome Editing for the Study of Hematopoietic Cells in Disease Models

Published on: October 3, 2019

12.4K
Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
08:27

Highly Efficient Gene Disruption of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9

Published on: April 10, 2018

13.6K

科学领域:

  • 血液学 血液学 血液学
  • 基因治疗 基因治疗
  • 遗传学 是一个遗传学.

背景情况:

  • 严重的血红蛋白病,如状细胞病和β-血病,对全球健康构成重大挑战.
  • 目前的基因治疗策略旨在通过增强胎儿血红蛋白 (HbF) 生产来实现功能治疗.
  • 克里斯普尔-Cas9技术允许精确地基因修饰造血干细胞.

研究的目的:

  • 审查基于CRISPR的基因编辑用于严重的血红蛋白病的现状和未来前景.
  • 评估现有的ex vivo治疗方法的可访问性和可扩展性.
  • 探索体内基因编辑的潜力,以获得更广泛的治疗.

主要方法:

  • 对关于状细胞疾病和β-thalassemia的CRISPR基因编辑现有文献的综述.
  • 分析当前的ex vivo治疗方案及其资源需求.
  • 评估新兴的体内基因编辑策略及其可行性.

主要成果:

  • 活体CRISPR基因编辑显示出通过增加HbF水平来治疗严重的血红蛋白病的前景.
  • 目前的ex vivo方法需要专门的设施和大量的资源,这阻碍了广泛的可访问性.
  • 活体基因编辑方法正在开发中,并有可能改善全球访问.

结论:

  • 基于CRISPR的疗法代表了严重血红蛋白病的功能治疗的有希望的途径.
  • 目前的ex vivo治疗方法的可用性是一个主要的限制,特别是在资源有限的环境中.
  • 开发体内基因编辑方法对于实现这些疾病的可扩展,可负担和全球可访问的治疗方法至关重要.